Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors

Mollica, A. and Pelliccia, S. and Famiglini, V. and Stefanucci, A. and Macedonio, G. and Benyhe, Sándor and Zádor, Ferenc and Erdei, Anna and Szűcs, Edina and Samavati, Reza and Dvorácskó, Szabolcs and Tömböly, Csaba (2017) Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 32 (1). pp. 444-451. ISSN 1475-6366

Preview

Text Exploring_the_first_Rimonabant_analog_opioid_peptide_hybrid_compound_as_bivalent_ligand_for_CB1_and_opioid_receptors_u.pdf Download (1MB) | Preview

Abstract

Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of micro-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be good candidates to investigate the existence of possible cross-talking or synergistic effects, also at sub-effective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2. The bivalent compound (9) has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release.

Actions (login required)

Edit Item